PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Pacira BioSciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$36.34+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $1.46B
P/E (TTM): 103.8
Dividend yield: –

Pacira BioSciences, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	726	701	675	667	542	430	421	337	287	276	249	198	86	39	16	15	15
Cost of Revenue	150	170	185	199	140	117	107	87	88	110	72	77	55	32	17	12	12
Gross Profit	577	531	490	468	401	312	314	250	199	166	177	120	31	6.95	-1.05	2.29	2.71
Research & Development	117	82	76	85	56	59	72	56	57	46	29	19	22	9.94	15	19	26
Selling, General & Admin	369	294	269	255	199	194	201	177	161	153	139	107	63	46	20	6.37	5.02
Operating Expenses	–	–	–	–	–	–	411	321	312	308	240	203	139	88	55	37	44
Total Costs & Expenses	707	774	587	607	452	383	411	321	–	–	–	–	–	–	–	–	–
Operating Income	19	-73	88	60	90	46	10	16	-25	-32	9.46	-5.17	-53	-49	-39	-23	-29
Interest Expense	17	17	20	40	32	26	24	22	18	7.06	7.73	8.28	7.25	1.81	4.78	3.96	1.72
Interest & Investment Income	23	20	11	4.54	0.90	4.63	7.38	6.50	4.08	1.32	0.68	0.38	0.26	0.28	0.26	0.15	0.08
Other Non-Operating Income	-2.32	10	-26	-11	-34	-26	-21	-16	-18	-5.82	-7.34	-8.38	-11	-2.98	-4.23	-4.44	-3.16
Merger & Restructuring Charges	3.67	8.53	1.11	0	0	-0.04	0.85	1.56	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	163	0	0	–	–	–	–	–	–	–	–	0	0	3.02	–	–
Gain (Loss) on Investments	–	–	–	–	-2.67	1.62	-4.32	-0.85	0	0	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	-0.19	0.01	-0.02	-1.01	-0.07	-2.13	-0.39	-0.01	-0.16	-0.03	0.00	-0.27	-0.01	-1.71
Legal Settlements	–	–	–	–	0	0	-3.50	–	–	–	–	–	–	–	–	–	–
Pretax Income	17	-63	62	13	56	20	-11	-0.43	-42	-38	2.12	-14	-64	-52	-43	–	–
Income Tax Expense	9.84	36	20	-2.61	14	-125	0.27	0.05	0.14	0.11	0.26	0.17	-0.44	0	0	–	–
Net Income	7.03	-100	42	16	42	146	-11	-0.47	-43	-38	1.86	-14	-64	-52	-43	-27	-32
EPS (Basic)(per share)	0.16	-2.15	0.91	0.35	0.95	3.41	-0.27	-0.01	-1.07	-1.02	0.05	-0.39	-1.93	-1.72	-2.64	-47.29	-55.32
EPS (Diluted)(per share)	0.16	-2.15	0.89	0.34	0.92	3.33	-0.27	-0.01	-1.07	-1.02	0.04	-0.39	-1.93	-1.72	-2.64	-47.29	-55.32
Shares Outstanding (Basic, Weighted)(shares)	45	46	46	46	44	43	42	41	40	37	37	35	33	30	16	0.57	0.57
Shares Outstanding (Diluted, Weighted)(shares)	45	46	52	47	46	44	42	41	40	37	41	35	33	30	16	0.57	0.57
EBITDA	110	5.41	163	152	118	66	30	29	-11	-19	21	4.87	-48	-44	-35	-19	-24

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 79.2%
Operating margin: 2.7%
Net margin: 2.0%
Return on equity, FY2025: 1.0%

Financial strength

Current ratio: 5.04
Debt to equity: 0.54
Debt to assets: 29.2%
Cash to current liabilities: 168.7%

Valuation

P/E ratio: 103.8
Price to sales: 1.96
Price to book: 2.18
Dividend yield: –